iBio (NYSE AMERICAN:IBIO) joined a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI), a consortium of more than 100 partner organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs.
Approximately $80-million from the federal government is being combined with more than $200-million in cost-share to support the development of tissue and organ manufacturing capabilities.
As part of continuing efforts to help revitalize American manufacturing and incentivize companies to invest in new technology development in the U.S., ARMI will lead the Advanced Tissue Biofabrication (ATB) initiative on behalf of the Department of Defense. ARMI also will focus on creating state-of-the-art manufacturing innovations in biomaterial and cell processing.
“We are pleased to join the ARMI consortium and contribute our expertise in biologics production,” Robert Kay, CEO and chairman of iBio, said in a statement.
He said iBio’s proven FastPharming System is uniquely suited to support the need for high-performing raw materials for biofabrication and cell culture, given the speed, consistency, safety and scalability of protein production in plants.
“We are looking forward to collaborating with the other esteemed members of ARMI/ATB to help advance biomaterial innovation for 3D bioprinting applications,” he added.
